These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32064583)

  • 1. Reliability and validity of the Vitiligo Signs of Activity Score (VSAS).
    van Geel N; Passeron T; Wolkerstorfer A; Speeckaert R; Ezzedine K
    Br J Dermatol; 2020 Nov; 183(5):883-890. PubMed ID: 32064583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hot spots for clinical signs of disease activity in vitiligo.
    Delbaere L; van Causenbroeck J; Duponselle J; Van Goethem C; Speeckaert R; van Geel N
    Exp Dermatol; 2024 Jan; 33(1):e14975. PubMed ID: 37975576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the dynamic changes in vitiligo: reliability and validity of the Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS).
    van Geel N; Depaepe L; Vandaele V; Mertens L; Van Causenbroeck J; De Schepper S; Van Coile L; Van Reempts A; De Vos AS; Papeleu J; Hoorens I; Mertens D; Wolkerstorfer A; Lommerts JE; Speeckaert R
    J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1334-1341. PubMed ID: 35398942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reliability of the Vitiligo Area Scoring Index measurement tool for vitiligo.
    Pourang A; Kohli I; Ezekwe N; Parks-Miller A; Mohammad TF; Huggins RH; Lim HW; Deal LS; Lukic T; Zhang F; Hamzavi I
    JAAD Int; 2024 Sep; 16():206-213. PubMed ID: 39040843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Analysis of the Most Used Versus the Recently Developed Vitiligo Activity and Extent Scores and Their Change with Treatment.
    Youssef R; Emad N; Mogawer RM
    Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37557162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and agreement testing of a new automated measurement method to determine facial vitiligo extent using standardized ultraviolet images and a dedicated algorithm.
    Marin Dit Bertoud Q; Bertold C; Ezzedine K; Pandya AG; Cherel M; Castillo Martinez A; Seguy MA; Abdallah M; Bae JM; Böhm M; Parsad D; Rosmarin D; Wolkerstorfer A; Bahadoran P; Blaise M; Dugourd PM; Philippo V; Delaval JM; Passeron T
    Br J Dermatol; 2023 Dec; 190(1):62-69. PubMed ID: 37615581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of the fingertip unit for assessing Facial Vitiligo Area Scoring Index.
    Bae JM; Zubair R; Ju HJ; Kohli I; Lee HN; Eun SH; Lyons AB; Vellaichamy G; Han TY; Lim HW; Hamzavi IH
    J Am Acad Dermatol; 2022 Feb; 86(2):387-393. PubMed ID: 34246695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical visible signs of disease activity in vitiligo: a systematic review and meta-analysis.
    van Geel N; Grine L; De Wispelaere P; Mertens D; Prinsen CAC; Speeckaert R
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1667-1675. PubMed ID: 31131483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinician-reported outcome measures for the assessment of vitiligo: A scoping review.
    van Geel N; Duponselle J; Delbaere L; Herbelet S; Eleftheriadou V; Ezzedine K; Forman M; Garg A; Hamzavi IH; Seneschal J; Spuls P; Terwee CB; Wolkerstorfer A; Speeckaert R; Pandya AG
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2231-2242. PubMed ID: 37602494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reference method for digital surface measurement of target lesions in vitiligo: a comparative analysis.
    van Geel N; Vandendriessche D; Vandersichel E; De Schepper S; Grine L; Mertens L; Vandaele V; Spoelders F; Bekkenk M; Wolkerstorfer A; Prinsen CA; Speeckaert R
    Br J Dermatol; 2019 May; 180(5):1198-1205. PubMed ID: 30207606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo.
    Sosa JJ; Currimbhoy SD; Ukoha U; Sirignano S; O'Leary R; Vandergriff T; Hynan LS; Pandya AG
    J Am Acad Dermatol; 2015 Aug; 73(2):272-5. PubMed ID: 26054430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative.
    van Geel N; Lommerts J; Bekkenk M; Wolkerstorfer A; Prinsen CAC; Eleftheriadou V; Taïeb A; Picardo M; Ezzedine K; Speeckaert R
    J Invest Dermatol; 2016 May; 136(5):978-984. PubMed ID: 26827762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presentations, Signs of Activity, and Differential Diagnosis of Vitiligo.
    Goh BK; Pandya AG
    Dermatol Clin; 2017 Apr; 35(2):135-144. PubMed ID: 28317523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa.
    Kirby JS; Butt M; King T
    Br J Dermatol; 2020 Apr; 182(4):940-948. PubMed ID: 31233623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reliability, Validity and Feasibility of the Vitiligo Extent Score (VES) and Self-Assessment Vitiligo Extent Score (SA-VES) Among Vitiligo Patients: A Cross-Cultural Validation.
    Chaweekulrat P; Silpa-Archa N; Apinuntham C; Chaiyabutr C; Wongpraparut C
    Clin Cosmet Investig Dermatol; 2021; 14():949-957. PubMed ID: 34349539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa.
    Thorlacius L; Garg A; Riis PT; Nielsen SM; Bettoli V; Ingram JR; Del Marmol V; Matusiak L; Pascual JC; Revuz J; Sartorius K; Tzellos T; van der Zee HH; Zouboulis CC; Saunte DM; Gottlieb AB; Christensen R; Jemec GBE
    Br J Dermatol; 2019 Sep; 181(3):483-491. PubMed ID: 30724351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability and validity of the Vitiligo Signs of Activity Score.
    Eleftheriadou V
    Br J Dermatol; 2020 Nov; 183(5):801-802. PubMed ID: 32458411
    [No Abstract]   [Full Text] [Related]  

  • 18. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis.
    Mohammed Vashist N; Samaan M; Mosli MH; Parker CE; MacDonald JK; Nelson SA; Zou GY; Feagan BG; Khanna R; Jairath V
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011450. PubMed ID: 29338066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using the Vitiligo Noticeability Scale in clinical trials: construct validity, interpretability, reliability and acceptability.
    Batchelor JM; Gran S; Leighton P; Howells L; Montgomery AA; Tan W; Ahmed I; Thomas KS
    Br J Dermatol; 2022 Oct; 187(4):548-556. PubMed ID: 35596714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a Patient Global Assessment for extent, severity and impact to define the severity strata for the Self Assessment Vitiligo Extent Score (SA-VES).
    van Geel N; Uitentuis SE; Zuidgeest M; Wolkerstorfer A; Bekkenk MW; Moock C; Van Goethem C; Verlaeckt E; Smet C; Grine L; Speeckaert R
    J Eur Acad Dermatol Venereol; 2021 Jan; 35(1):216-221. PubMed ID: 32452565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.